Merck Ends Nemtabrutinib Program After Phase 3 Signal
The company discontinued three Bellwave trials in CLL and SLL after a data monitoring committee said the drug's risks may outweigh its benefits, halting a program bought for $2.7 billion.
, updated . 1-minute read.

Merck & Co. has discontinued its BTK inhibitor nemtabrutinib after an external data monitoring committee review suggested the drug's risks may outweigh its benefits in chronic lymphocytic leukemia, Fierce Biotech reported on Wednesday. Merck first stopped the phase 3 Bellwave-011 study and then, after confirming the committee's conclusions, halted the broader clinical program, including Bellwave-008 and Bellwave-010. The Bellwave studies evaluated nemtabrutinib both alone and in combination across different groups of patients with CLL or small lymphocytic lymphoma.
The decision ends a development effort that began with Merck's $2.7 billion purchase of ArQule in 2019. At that time, nemtabrutinib, also called ARQ 531 or MK-1026, was showing durable responses in early testing among patients with B-cell malignancies. At least six companies weighed a transaction with ArQule during 2018 and 2019, and Merck ultimately paid over 100 percent more than the target's share price to close the deal.
Merck initially valued the acquired research and development project at $2.3 billion. In 2021, Merck lowered that figure by $275 million, citing revisions to anticipated development costs and a postponed expected launch. The company recorded a $1.7 billion charge in 2022 after discussions with regulators showed development would take longer than expected; in its latest annual report, Merck listed the project's balance at $418 million.
The purchase placed Merck against Eli Lilly, which acquired a competing BTK inhibitor in its $8 billion buyout of Loxo Oncology. Lilly's drug, Jaypirca, went on to win FDA approval in 2023 and received an expanded indication in CLL and SLL in 2025. Fierce Biotech's report did not give the specific data reviewed by the monitoring committee or the number of patients enrolled in Bellwave-011. Clinical Observer reported in November that the FDA approved Merck's oral PCSK9 inhibitor Lipfendra, and Clinical Observer reported in October that Merck and Moderna released phase 3 cancer vaccine data early after a leak.
Update, November 19, 2026
Merck has publicly confirmed the discontinuation in a statement, CancerNetwork reported Thursday. Marjorie Green, Merck’s head of oncology clinical development, said the company decided after reviewing BELLWAVE-011 data to stop the drug across the entire program. “We continue to pursue solutions for patients with hematologic malignancies and focus on advancing our hematology pipeline to help more patients with blood cancers,” she said. The report also gave new details on the halted study: BELLWAVE-011 compared nemtabrutinib with investigator’s choice of ibrutinib or acalabrutinib in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma, with objective response rate and progression-free survival as co-primary endpoints. Merck said data analyses for BELLWAVE-008 and BELLWAVE-010 are ongoing and results will be shared, but no efficacy or safety figures were disclosed.
Sources: Fierce Biotech, Clinical Observer (1, 2), CancerNetwork
Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.